Although there are currently no cGAS-STING inhibitors under preclinical research for AD, in the findings described above there are some potential therapeutic targets including cGAMP [146] and PQBP1 [148] to be further validated as novel drug targets in AD. This evidence concerns the gene PQBP1 and Alzheimer disease.